Advertisement

Free triiodothyronine (fT3) and B-type natriuretic peptide (BNP) predict in-hospital mortality after valve surgery

  • Hiroshi MukaidaEmail author
  • Masakazu Hayashida
  • Satoshi Matsushita
  • Daisuke Endo
  • Atsumi Oishi
  • Akie Shimada
  • Hiroaki Hata
  • Kan Kajimoto
  • Taira Yamamoto
  • Atsushi Amano
Original Article
  • 22 Downloads

Abstract

Background

Increased B-type natriuretic peptide (BNP) and decreased free triiodothyronine (fT3) are associated with increased mortality after cardiac surgery. However, previous studies have addressed mortality primarily in patients undergoing coronary artery bypass graft, and not in those undergoing valve surgery. We assessed abilities of BNP and fT3 to predict mortality after valve surgery.

Methods

This retrospective study included 1050 consecutive patients who underwent valve surgery with normothermic cardiopulmonary bypass (CPB). Predictors of in-hospital mortality were identified with logistic regression analyses. Cutoff values were determined with receiver operating curve analyses.

Results

There were 23 deaths (2.2%). By univariate analyses, fT3, log-transformed BNP (log BNP), cholinesterase, estimated glomerular filtration rate, and albumin were profoundly associated with in-hospital mortality (p < 0.0001 for each). By a multivariate analysis, however, only fT3 and log BNP remained significant (p = 0.0053 and p = 0.0449, respectively). fT3 and log BNP remained significant after adjustment for CPB time, and also after adjustment for the EuroSCORE II or JapanSCORE (p < 0.05 for each). Odds ratio and 95% confidence interval from univariate binary analysis for in-hospital mortality were 7.22 (3.12–17.58) for fT3 ≤ 2.21 pg/mL, 6.01 (2.54–15.77) for BNP ≥ 219 pg/mL, and 9.79 (4.21–22.74) for both combined (p < 0.0001 for each).

Conclusions

fT3 and BNP predict in-hospital mortality after valve surgery, independent of each other, independent of CPB time, and independent of established mortality risk SCOREs. Additions of fT3 and BNP may enhance predictive utilities of established mortality risk SCOREs.

Keywords

B-type natriuretic peptide (BNP) Cardiopulmonary bypass (CPB) Free triiodothyronine (fT3) Heart valve surgery Mortality 

Notes

Acknowledgements

We thank all the staff associated with cardiac surgery for their assistance in conducting this study.

Compliance with ethical standards

Conflicts of interest

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

References

  1. 1.
    Guida P, Mastro F, Scrascia G, Whitlock R, Paparella D. Performance of the European system for cardiac operative risk evaluation II: a meta-analysis of 22 studies involving 145,592 cardiac surgery procedures. J Thorac Cardiovasc Surg. 2014;148:3049–57.CrossRefGoogle Scholar
  2. 2.
    Hansen LS, Hjortdal VE, Andreasen JJ, Mortensen PE, Jakobsen CJ. 30-day mortality after coronary artery bypass grafting and valve surgery has greatly improved over the last decade, but the 1-year mortality remains constant. Ann Card Anaesth. 2015;18:138–42.CrossRefGoogle Scholar
  3. 3.
    Mitchell J, Webb ST. Is brain natriuretic peptide a marker for adverse postoperative outcomes in patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg. 2011;12:467–72.CrossRefGoogle Scholar
  4. 4.
    Fox AA, Shernan SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, et al. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008;136:452–61.CrossRefGoogle Scholar
  5. 5.
    Cuthbertson BH, Croal BL, Rae D, Gibson PH, McNeilly JD, Jeffrey RR, et al. N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study. Br J Anaesth. 2009;103:647–53.CrossRefGoogle Scholar
  6. 6.
    Fox AA, Muehlschlegel JD, Body SC, Shernan SK, Liu KY, Perry TE, et al. Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting. Anesthesiology. 2010;112:842–51.CrossRefGoogle Scholar
  7. 7.
    Heringlake M, Garbers C, Käbler JH, Anderson I, Heinze H, Schön J, et al. Preoperative cerebral oxygen saturation and clinical outcomes in cardiac surgery. Anesthesiology. 2011;114:58–69.CrossRefGoogle Scholar
  8. 8.
    Cerillo AG, Storti S, Kallushi E, Haxhiademi D, Miceli A, Murzi M, et al. The low triiodothyronine syndrome: a strong predictor of low cardiac output and death in patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2014;97:2089–95.CrossRefGoogle Scholar
  9. 9.
    Gardner SC, Grunwald GK, Rumsfeld JS, Cleveland JC Jr, Schooley LM, Gao D, et al. Comparison of short-term mortality risk factors for valve replacement versus coronary artery bypass graft surgery. Ann Thorac Surg. 2004;77:549–56.CrossRefGoogle Scholar
  10. 10.
    Kurazumi H, Mikamo A, Fukamitsu G, Kudou T, Sato M, Suzuki R, et al. Validation of the JapanSCORE versus the logistic EuroSCORE for predicting operative mortality of cardiovascular surgery in Yamaguchi University Hospital. Gen Thorac Cardiovasc Surg. 2011;59:599–604.CrossRefGoogle Scholar
  11. 11.
    Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010;51:151–63.CrossRefGoogle Scholar
  12. 12.
    Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013;24:286–9.CrossRefGoogle Scholar
  13. 13.
    Moura Neto A, Zantut-Wittmann DE. Abnormalities of thyroid hormone metabolism during systemic illness: the low T3 syndrome in different clinical settings. Int J Endocrinol. 2016;2016:2157583.CrossRefGoogle Scholar
  14. 14.
    Lamprou V, Varvarousis D, Polytarchou K, Varvarousi G, Xanthos T. The role of thyroid hormones in acute coronary syndromes: prognostic value of alterations in thyroid hormones. Clin Cardiol. 2017;40:528–33.CrossRefGoogle Scholar
  15. 15.
    Wang B, Liu S, Li L, Yao Q, Song R, Shao X, et al. Non-thyroidal illness syndrome in patients with cardiovascular diseases: a systematic review and meta-analysis. Int J Cardiol. 2017;226:1–10.CrossRefGoogle Scholar
  16. 16.
    Yamamoto M, Hayashida M, Kakemizu-Watanabe M, Ando N, Mukaida H, Kawagoe I, et al. B-Type natriuretic peptide and hemoglobin are two major factors significantly associated with baseline cerebral oxygen saturation measured using the INVOS oximeter in patients undergoing off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2018;32:187–96.CrossRefGoogle Scholar
  17. 17.
    Biondi B. The management of thyroid abnormalities in chronic heart failure. Heart Fail Clin. 2019;15(3):393–8.CrossRefGoogle Scholar
  18. 18.
    Einfeldt MN, Olsen AS, Kristensen SL, Khalid U, Faber J, Torp-Pedersen C, et al. Long-term outcome in patients with heart failure treated with levothyroxine: an observational nationwide cohort study. J Clin Endocrinol Metab. 2019;104:1725–34.CrossRefGoogle Scholar
  19. 19.
    Choi YS, Shim JK, Song JW, Song Y, Yang SY, Kwak YL. Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 2013;27:1218–23.CrossRefGoogle Scholar
  20. 20.
    Chuang CP, Jong YS, Wu CY, Lo HM. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am J Cardiol. 2014;113:845–50.CrossRefGoogle Scholar
  21. 21.
    Pfister R, Strack N, Wielckens K, Malchau G, Erdmann E, Schneider CA. The relationship and prognostic impact of low-T3 syndrome and NT-pro-BNP in cardiovascular patients. Int J Cardiol. 2010;144:187–90.CrossRefGoogle Scholar
  22. 22.
    Zhang B, Peng W, Wang C, Li W, Xu Y. A low fT3 level as a prognostic marker in patients with acute myocardial infarctions. Intern Med. 2012;51:3009–15.CrossRefGoogle Scholar
  23. 23.
    Brozaitiene J, Mickuviene N, Podlipskyte A, Burkauskas J, Bunevicius R. Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type natriuretic peptide for patients after acute coronary syndromes: a longitudinal observational study. BMC Cardiovasc Disord. 2016;16:45.CrossRefGoogle Scholar
  24. 24.
    Yazıcı S, Kırış T, Ceylan US, Terzi S, Erdem A, Atasoy I, et al. Relation of low T3 to one-year mortality in non-ST-elevation acute coronary syndrome patients. J Clin Lab Anal. 2017;31:e22036.CrossRefGoogle Scholar
  25. 25.
    Galli E, Lancellotti P, Sengupta PP, Donal E. LV mechanics in mitral and aortic valve diseases: value of functional assessment beyond ejection fraction. JACC Cardiovasc Imaging. 2014;7:1151–66.CrossRefGoogle Scholar
  26. 26.
    Ishigaki T, Shingu Y, Katoh N, Wakasa S, Katoh H, Ooka T, et al. Perioperative changes of the slope in the preload recruitable stroke work relationship by a single-beat technique after mitral valve surgery in functional mitral regurgitation with non-ischemic dilated cardiomyopathy. Gen Thorac Cardiovasc Surg. 2019.  https://doi.org/10.1007/s11748-019-01164-w.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2019

Authors and Affiliations

  • Hiroshi Mukaida
    • 1
    • 2
    Email author
  • Masakazu Hayashida
    • 3
  • Satoshi Matsushita
    • 1
  • Daisuke Endo
    • 1
  • Atsumi Oishi
    • 1
  • Akie Shimada
    • 1
  • Hiroaki Hata
    • 1
  • Kan Kajimoto
    • 1
  • Taira Yamamoto
    • 1
  • Atsushi Amano
    • 1
  1. 1.Department of Cardiovascular Surgery, Faculty of MedicineJuntendo UniversityTokyoJapan
  2. 2.Department of Clinical EngineeringJuntendo University HospitalTokyoJapan
  3. 3.Department of Anesthesiology and Pain Medicine, Faculty of MedicineJuntendo UniversityTokyoJapan

Personalised recommendations